Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 18/20 | 0.62 |
| ▸ | MAPK12 | P53778 | 18/20 | 0.62 |
| ▸ | MAPK11 | Q15759 | 18/20 | 0.62 |
| ▸ | MAPK14 | Q16539 | 18/20 | 0.62 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5116064 | 0.95 | MAPK14 (0.59) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5119941 | 0.87 | MAPK14 (0.67) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5126280 | 0.87 | MAPK14 (0.56) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5116347 | 0.85 | MAPK14 (0.65) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5120005 | 0.85 | MAPK14 (0.65) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5112021 | 0.85 | MAPK13 (0.67) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5119972 | 0.85 | MAPK14 (0.64) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5114881 | 0.84 | MAPK14 (0.68) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5120125 | 0.84 | MAPK14 (0.63) | MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL5116364 | 0.84 | MAPK14 (0.63) | MAPK13MAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080167314-A1 | Condensed Imidazole Compound And Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080167314-A1 | Condensed Imidazole Compound And Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080167314-A1 | Condensed Imidazole Compound And Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-10 | — | — | US | disclosed |
| EP-1832588-A1 | CONDENSED IMIDAZOLE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-09-12 | — | — | EP | disclosed |
| EP-1832588-A1 | CONDENSED IMIDAZOLE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2007-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167314-A1 | Condensed Imidazole Compound And Use Thereof | MAPK13, MMP13, MAPK3 | MAPK13 1/4885MAPK12 9/4885MAPK11 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.